Nicholas J. Vogelzang

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

Nicholas J. Vogelzang
Born (1949-12-13) December 13, 1949
Holland, Michigan
DiedSeptember 20, 2022(2022-09-20) (aged 72)
Las Vegas, Nevada, U.S.
Alma materUniversity of Illinois School of Medicine
OccupationOncologist
EmployerComprehensive Cancer Centers of Nevada
Known forCancer research
Board member ofChair and medical director of the Developmental Therapeutics Committee and co-chair of the Genitourinary Committee for U.S. Oncology Research

Career

Vogelzang joined Comprehensive Cancer Centers of Nevada in 2009 as a medical oncologist and serves as medical director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research.[1] Since 2004, he has been Head of the Genitourinary Oncology and Clinical Professor of Medicine for the University of Nevada School of Medicine in Las Vegas and Reno, Nevada.

He served as Director, Executive Vice President for Academic Affairs and Professor at Nevada Cancer Institute (NVCI) from 2004 to 2009.

During his tenure at the University of Chicago, he served as Professor of Medicine and Surgery (Urology) (1993 to 2003), Director for the University of Chicago Cancer Research Center (1999–2003), and was named the first Fred C. Buffett Professor in Medicine and chair in Genitourinary Oncology (1999–2003).[2]

Vogelzang received his M.D. from the University of Illinois at Chicago in 1974. He completed his internship, residency and chief residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago, followed by his fellowship in medical oncology at the University of Minnesota in Minneapolis. Vogelzang became the first editor of the Textbook of Genitourinary Oncology and remains the lead editor today.

Research

In 2002, Vogelzang directed the largest Phase II trial for mesothelioma using pemetrexed (brand name Alimta, by Eli Lilly). Pemetrexed is an antifolate, a class of drugs that targets the folic acid metabolic pathway. The results of the trial showed tumors shrank in 41 percent of patients on pemetrexed in combination with a more commonly used chemotherapy agent called cisplatin. Only 17 percent of patients receiving cisplatin alone experienced tumor shrinkage. Additionally, those on the pemetrexed combination lived nearly three months longer than those on cisplatin alone.[3][4]

Active research support

Vogelzang is actively involved in many research studies to test new therapies and treatments including:

  • A double-blind, randomised, multiplied dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. The study began in October 2010 and is supported by Algeta USA.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy. The study began in March 2010 and is supported by Cougar Biotechnology.
  • A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer. The study began in April 2009 and is supported by Cougar Biotechnology.
  • A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer. The study began in June 2010 and is supported by Dendreon.
  • A Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer. The study began in September 2009 and is supported by Tokai.

Professional memberships

Vogelzang served on committees for the American Society of Clinical Oncology (ASCO), as well as its board of directors from 1993 to 1996, and is a former president of the Illinois Division of the American Cancer Society. Vogelzang was the principal investigator at the University of Chicago for Cancer and Leukemia Group B (CALGB) from 1988 to 1999, and chair of the CALGB Prostate Committee from 1993 to 1999.

He is a founding board member of the Mesothelioma Applied Research Foundation (MARF) and a member the American Association for Cancer Research, the American Urological Association, the Society of Urologic Oncology and the European Society for Medical Oncology. Vogelzang is the 2012 Chair for the American Society of Clinical Oncology's (ASCO) Cancer Communications Committee, the current Vice Chair of the GU Committee and a member of the GU Translational Medicine Intergroup Committee for Southwest Oncology Group. For more than ten years, Vogelzang has served on the Medical and Scientific Advisory Boards for Us TOO, a prostate cancer education and support network for persons affected by prostate cancer.

Vogelzang is also a current or past member of several medical societies including:

Corporate relationships

Vogelzang is a corporate consultant for the following companies: Aveo Pharmaceuticals Inc., Celgene Corporation, Dendreon, Exelixis Inc., Novartis AG, OncoGeneX/Teva Pharmaceutical Industries Ltd., Veridex, and Viamet.

He is also a member of the speakers' bureaus for Caris Life Sciences, Dendreon, Eli Lilly and Company, Inc., Novartis AG, and Sanofi-Aventis U.S.

Published works

In the media

Awards and honors

Vogelzang has been recognized for his work by many of the leading medical groups and research organizations in the United States. Some of his notable honors include:

  • Member of the Board of Advisors, Johns Hopkins Greenberg Bladder Cancer Institute - 2014
  • Named one of the "Top Doctors - Medical Oncology" in Vegas Seven - May 2014[6]
  • Laureate Award and medallion of The ACP Nevada Chapter - 2013
  • Distinguished Physician of the year, The Nevada State Medical Association, 2013
  • Named one of the "Best Physicians in Southern Nevada as chosen by their peers" in Desert Companion - August 2012[7]
  • Received Everyday Hero Award from American Red Cross Las Vegas - October 2011[8]
  • Named Healthcare Headliner by VEGAS Inc. magazine - October 2011
  • Awarded Gold Certificate of Excellence by National Cancer Institute - October 2011
  • Named Top Doctor by U.S. News & World Report - 2011[5]
  • Honored with a service award for his more than 10 years on the board of the Mesothelioma Applied Research Foundation - June 2011
  • "Best Doctors in Las Vegas: Research" by Las Vegas Life - 2011
  • Schonfeld Memorial Lecture, Kidney Cancer Association 20th Anniversary meeting - Chicago, October 2010
  • Keynote Speaker, Japanese Society for Renal Cancer, 40th Anniversary - Tokyo, June 2010

References
  1. "Nicholas J. Vogelzang, MD, FASCO, FACP - Comprehensive Cancer Centers of Nevada". Cccnevada.com. Retrieved 23 June 2018.
  2. "Vogelzang named first Fred C. Buffett Professor, begins cancer center directorship". Chronicle.uchicago.edu. Retrieved 23 June 2018.
  3. "Mesothelioma Study Shows Benefit from Pemetrexed (Alimta), an antifolate". Mesotheliomaweb.org. Retrieved 23 June 2018.
  4. "Advanced NS NSCLC Treatment - ALIMTA (pemetrexed for injection)". Alimta.com. Retrieved 23 June 2018.
  5. "Dr. Nicholas Vogelzang, Hematologist in Las Vegas, NV | US News Doctors". Archived from the original on 2016-03-05. Retrieved 2014-06-19.
  6. "Medical Oncology | Vegas Seven". Archived from the original on 2014-05-09. Retrieved 2014-06-19.
  7. "Top Doctors: The list". Desertcompanion.com. Retrieved 23 June 2018.
  8. "Las Vegas Review-Journal". Las Vegas Review-Journal. Archived from the original on 2016-04-06. Retrieved 23 June 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.